Percutaneous catheter drainage of pancreatic pseudocysts.
Pancreatic pseudocysts represent a complication of severe pancreatic inflammatory disease. Although operative drainage is the cornerstone of therapy for pseudocysts, we have undertaken percutaneous catheter drainage in a selected group of 28 patients over a six-year period (1982-88). This represents 42 per cent of pseudocyst patients managed by the senior author and 1.7 per cent of admissions for pancreatitis at the Medical University Hospitals during that period of time. There were 26 men and two women with an age range of 26-66 years (mean = 42.1). Twenty-six patients had alcohol abuse as the cause of pancreatitis; two were due to surgical trauma. Nondilated pancreatic ducts were demonstrated in 25 patients. Six had pancreatic ascites associated with pseudocysts. Four had previous operative drainage (2 internal and 2 external drainage procedures). Five patients received octreotide acetate, a synthetic peptide which mimics the action of somatostatin, in an attempt to aid closure of external fistulas. The mean length of catheter drainage was 48 days (range 7-210 days). Eight (29%) patients developed procedure-related complications (1 pneumothorax, 1 sheared guidewire, six drain tract infections). There was no mortality. Successful resolution of pseudocysts was achieved in 26 patients (93%). Two patients subsequently had elective caudal pancreaticojejunostomy (CPJ), and one lateral pancreaticojejunostomy (LPJ) to drain obstructed pancreatic ducts. One patient has required repeat external drainage. Percutaneous external drainage is successful in pseudocyst eradication. When underlying pancreatic pathology remains uncorrected, elective surgical decompression of obstructed, dilated ducts may be necessary.
Adams
D B
DB
Department of Surgery, Medical University of South Carolina, Charleston 29425.
Harvey
T S
TS
Anderson
M C
MC
D000328:Adult; D000368:Aged; D001201:Ascites / Q000628:therapy; D001424:Bacterial Infections / Q000209:etiology; D002404:Catheterization / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D004322:Drainage / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D004868:Equipment Failure; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D010185:Pancreatic Fistula / Q000188:drug therapy / Q000209:etiology; D010192:Pancreatic Pseudocyst / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D010195:Pancreatitis / Q000628:therapy; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
D015282:Octreotide